Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Best Practices for Incorporating LAIs into Treatment Planning for Schizophrenia

Premiere Date: Tuesday, December 29, 2020

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. ABIM (MOC)
  4. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, December 29, 2021
Note: Credit Is No Longer Available


John M. Kane, MDJohn M. Kane, MD 
Senior Vice President, Behavioral Health Services, Northwell Health
New Hyde Park, NY
Chairman, Department of Psychiatry, Zucker Hillside Hospital
Glen Oaks, NY
Professor and Chairman of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY

Statement of Need

Schizophrenia is an all-too-often chronic, debilitating disorder that impedes quality of life and psychosocial functioning. Implementation of effective therapy that promotes sustained recovery often poses a challenge for both clinicians and patients. Long-acting injectables (LAIs) can play a critical role in relapse prevention and rehospitalization, and subsequently, recovery and restoration of function.

This CME Outfitters BriefCase will guide clinicians through best practices to identify patients with schizophrenia who are ideal candidates for LAIs as well as effective communication strategies to facilitate the discussion of using LAIs in these patients.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Identify patients with schizophrenia who are ideal candidates for LAI therapies and strategies for transitioning from oral therapies.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Identify patients with schizophrenia who are ideal candidates for LAI therapies and strategies for transitioning from oral therapies.

Financial Support

Supported by an educational grant from Otsuka America Pharmaceutical, Inc., and Lundbeck.

Target Audience

Psychiatrists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Enduring: 0376-0000-20-119-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPN MOC: ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kane reports that he receives grants from Janssen Pharmaceuticals, Inc.; Lundbeck; and Otsuka America Pharmaceutical, Inc. He is a consultant for ACADIA Pharmaceuticals Inc.; Alkermes; Allergan; F. Hoffmann-La Roche; Intra-Cellular Therapies, Inc.; Lundbeck; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Johnson & Johnson; LB Pharmaceuticals, Inc.; Merck & Co., Inc.; Minerva Neurosciences; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Reviva Pharmaceuticals Inc.; Saladax Biomedical, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teva. He is a stock shareholder of Vanguard Research Group; and LB Pharmaceuticals, Inc.

Michael J. Franks, MSN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download